Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

Inclusion criteria:

- Diagnosed with CD and reconfirmed in previous 2 years by a radiologic or endoscopic
assessment including histology.

- CDAI (Crohn's Disease Activity Index) score of 220-450 after 1 week of screening.

- CRP (C-Reactive Protein) level of >4mg at screening.

Exclusion criteria:

- Significantly abnormal laboratory tests or ECG (electrocardiogram) results.

- Current use of an elemental diet or parenteral nutrition.

- Clinically significant positive stool culture.

- Ongoing neoplastic disease of the bowel.

- Bowel perforation other than fistulae.

- Has an ileostomy or colostomy.

- Fixed symptomatic gastrointestinal (GI) stricture within 6 months or obstructive
symptoms within 3 months of screening.

- Any bowel resection within 12 months of screening or bowel resection without
subsequent demonstration of recurrence of active CD.

- More than 100cm of bowel resected.

- Non-curative bowel surgery with 2 months of screening.

- Symptoms attributed to short bowel syndrome.

- Uncontrolled bacterial, viral, or fungal infection or congenital or acquired
immunodeficiency.

- Women who are pregnant, breast feeding, or planning to become pregnant during the
study.

Permitted medications:

- Less than or equal to 20mg/day oral corticosteroids for at least 4 weeks prior to
screening and on stable doses for 2 weeks prior to screening.

- Azathioprine and 6-MP (6-Mercaptopurine) stable dose for 3 months prior to screening.

- 5-ASA (5-Aminosalicylic acid) stable dose for 1 month prior to screening.

Prohibited medications:

- Greater than 20mg/day oral corticosteroids, or systemic intravenous corticosteroids,
or antibiotics as a treatment for CD within 4 weeks prior to screening.

- Cyclosporine or methotrexate during the 2 months prior to screening.

- Infliximab or other biological treatments within 3 months prior to screening.